# Contineum Therapeutics, Inc. (CTNM)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $230M  
**Price:** $11.86 (+4.96%)

> Continua Therapeutics Inc. is a biotechnology company focused on the development and commercialization of innovative therapeutic solutions. Its primary function lies in advancing novel drug candidates aimed at addressing unmet medical needs within the healthcare sector. The company emphasizes research and development, with a focus on diseases that currently lack effective treatment options, potentially impacting various medical fields such as oncology, neurology, and autoimmune disorders. Continua Therapeutics Inc. is significant in the market due to its commitment to pioneering next-generation pharmaceuticals that could redefine standard treatment protocols. Through strategic collaborations and a robust pipeline of research projects, the company plays a critical role in the biotech industry, pushing the boundaries of medical science.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2024 | — | — | -$51M | -$42M | — |
| 2023 | $50M | — | $16M | $23M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2024 | $213M | $15M | $198M | $22M | — |
| 2023 | $130M | $6M | -$68M | $16M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$55M | $231,000 | -$56M |
| 2024 | -$33M | $514,000 | -$33M |
| 2023 | $19M | $414,000 | $19M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CTNM)